Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA2 | P47869 | 14/20 | 0.55 |
| ▸ | GABRB2 | P47870 | 14/20 | 0.55 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
| ▸ | CNR1 | P21554 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24208712 | 0.84 | CNR1 (0.60) | CNR2CNR1 | |
| SCHEMBL24208915 | 0.82 | CNR1 (0.58) | CNR2CNR1 | |
| SCHEMBL24208703 | 0.82 | CNR1 (0.58) | CNR2CNR1 | |
| SCHEMBL30513027 | 0.82 | CNR1 (0.59) | CNR1 | |
| SCHEMBL24209030 | 0.82 | CNR1 (0.59) | CNR1 | |
| SCHEMBL25210484 | 0.82 | CNR1 (0.59) | CNR1 | |
| SCHEMBL27639293 | 0.81 | GABRA2 (0.59) | GABRA2GABRB2OPRL1 | |
| SCHEMBL24208891 | 0.81 | CNR1 (0.47) | CNR2CNR1 | |
| SCHEMBL24208783 | 0.79 | CNR1 (0.72) | CNR2CNR1 | |
| SCHEMBL25198056 | 0.79 | CNR1 (0.72) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655238-B2 | MMPL3 inhibitors, compositions and uses thereof | SHANGHAITECH UNIVERSITY (CN) | 2023-05-23 | — | — | US | claimed |
| US-11655238-B2 | MMPL3 inhibitors, compositions and uses thereof | SHANGHAITECH UNIVERSITY (CN) | 2023-05-23 | — | — | US | disclosed |
| US-11655238-B2 | MMPL3 inhibitors, compositions and uses thereof | SHANGHAITECH UNIVERSITY (CN) | 2023-05-23 | — | — | US | disclosed |
| US-20220017492-A1 | MMPL3 INHIBITORS, COMPOSITIONS AND USES THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2022-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655238-B2 | MMPL3 inhibitors, compositions and uses thereof | TIMP3, AFG3L2, MMP3 | GABRA2 4541/4885GABRB2 4587/4885OPRL1 3496/4885 |
| US-20220017492-A1 | MMPL3 INHIBITORS, COMPOSITIONS AND USES THEREOF | TIMP3, AFG3L2, MMP3 | GABRA2 4541/4885GABRB2 4587/4885OPRL1 3496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.